Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VRCOR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
anti-FOLR1-151-K-LOCK-D5
|
|||||
| Synonyms |
151-K-LOCK-D5; ADC-5
Click to Show/Hide
|
|||||
| Organization |
SORRENTO THERAPEUTICS, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
undisclosed
|
|||||
| Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
| Payload Name |
AU2023267043A1 ADC-5 Payload
|
Payload Info | ||||
| Linker Name |
AU2023267043A1 ADC-5 Linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
77.29%
|
|||
| Method Description |
The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
|
||||
| In Vivo Model | NSCLC cancer PDX model LU-01-1618 | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
0.97%
|
|||
| Method Description |
The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
|
||||
| In Vivo Model | IGROV1 tumor xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
1.00%
|
|||
| Method Description |
The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
|
||||
| In Vivo Model | IGROV1 tumor xenograft model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
105.97%
|
|||
| Method Description |
The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
|
||||
| In Vivo Model | NSCLC cancer PDX model LU-01-1618 | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
111.94%
|
|||
| Method Description |
The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
|
||||
| In Vivo Model | NSCLC cancer PDX model LU-01-1618 | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
116.16%
|
|||
| Method Description |
The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
|
||||
| In Vivo Model | NSCLC cancer PDX model LU-01-1618 | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
116.16%
|
|||
| Method Description |
The anti-tumor efficacy of a single dose of 1.5 mg/kg 151-K-Lock-D5 (ADC-5)
|
||||
| In Vivo Model | IGROV1 tumor xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.55 nM | High IGROV1 expression (IGROV1 +++) | ||
| Method Description |
IC50 Values (nM) of anti-FOLR1-151-K-LOCK-D5 and their corresponding controls in Human Tumor Cells IGROV1.
|
||||
| In Vitro Model | Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma | IGROV1 cells | CVCL_1304 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 15 nM | Low SKOV-3 expression ( SKOV-3 +) | ||
| Method Description |
IC50 Values (nM) of anti-FOLR1-151-K-LOCK-D5 and their corresponding controls in Human Tumor Cells SKOV-3
|
||||
| In Vitro Model | Ovarian serous adenocarcinoma | SKOV-3 cells | CVCL_0532 | ||